TWI766831B - 具螯合錯合物及核苷/核苷酸類似物hbv聚合酶抑制劑之組合物及其用於治療hbv感染或hbv/hdv共感染之用途 - Google Patents

具螯合錯合物及核苷/核苷酸類似物hbv聚合酶抑制劑之組合物及其用於治療hbv感染或hbv/hdv共感染之用途 Download PDF

Info

Publication number
TWI766831B
TWI766831B TW104122636A TW104122636A TWI766831B TW I766831 B TWI766831 B TW I766831B TW 104122636 A TW104122636 A TW 104122636A TW 104122636 A TW104122636 A TW 104122636A TW I766831 B TWI766831 B TW I766831B
Authority
TW
Taiwan
Prior art keywords
hbv
nucleic acid
nucleoside
chelate complex
composition
Prior art date
Application number
TW104122636A
Other languages
English (en)
Chinese (zh)
Other versions
TW201613617A (en
Inventor
安德魯 維隆
Original Assignee
加拿大商雷普利可公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI766831(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 加拿大商雷普利可公司 filed Critical 加拿大商雷普利可公司
Publication of TW201613617A publication Critical patent/TW201613617A/zh
Application granted granted Critical
Publication of TWI766831B publication Critical patent/TWI766831B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
TW104122636A 2014-07-10 2015-07-13 具螯合錯合物及核苷/核苷酸類似物hbv聚合酶抑制劑之組合物及其用於治療hbv感染或hbv/hdv共感染之用途 TWI766831B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US62/022,846 2014-07-10
US201462091943P 2014-12-15 2014-12-15
US62/091,943 2014-12-15

Publications (2)

Publication Number Publication Date
TW201613617A TW201613617A (en) 2016-04-16
TWI766831B true TWI766831B (zh) 2022-06-11

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104122636A TWI766831B (zh) 2014-07-10 2015-07-13 具螯合錯合物及核苷/核苷酸類似物hbv聚合酶抑制劑之組合物及其用於治療hbv感染或hbv/hdv共感染之用途

Country Status (33)

Country Link
US (1) US9603865B2 (sl)
EP (1) EP3166615B1 (sl)
JP (2) JP2017521433A (sl)
KR (2) KR20170029577A (sl)
CN (2) CN113750112A (sl)
AU (1) AU2015286199B2 (sl)
BR (1) BR112017000320B1 (sl)
CA (1) CA2954182C (sl)
CL (1) CL2017000008A1 (sl)
CU (1) CU20170001A7 (sl)
DK (1) DK3166615T3 (sl)
DO (1) DOP2017000002A (sl)
EA (1) EA036745B1 (sl)
EC (1) ECSP16097355A (sl)
ES (1) ES2963814T3 (sl)
FI (1) FI3166615T3 (sl)
HK (1) HK1231402A1 (sl)
HR (1) HRP20231400T1 (sl)
HU (1) HUE064449T2 (sl)
IL (1) IL249660B (sl)
LT (1) LT3166615T (sl)
MD (1) MD4760C8 (sl)
MX (1) MX2017000053A (sl)
MY (1) MY178087A (sl)
NZ (1) NZ727583A (sl)
PH (1) PH12017500010A1 (sl)
PL (1) PL3166615T3 (sl)
PT (1) PT3166615T (sl)
RS (1) RS64833B1 (sl)
SG (1) SG11201700073PA (sl)
SI (1) SI3166615T1 (sl)
TW (1) TWI766831B (sl)
WO (1) WO2016004525A1 (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020097342A1 (en) * 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US11166976B2 (en) * 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021119325A1 (en) * 2019-12-12 2021-06-17 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN112010905B (zh) * 2020-05-07 2021-09-03 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦晶型及其应用
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN114057816A (zh) * 2020-07-30 2022-02-18 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
WO2022109129A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
CA3224600A1 (en) 2021-07-09 2023-01-12 Glaxosmithkline Intellectual Property (No.3) Limited Use of oligonucleotides for individuals with renal impairment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201408309A (zh) * 2012-08-30 2014-03-01 Replicor Inc 用於治療ｂ型肝炎及ｄ型肝炎感染之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
EP2330194A3 (en) 2002-09-13 2011-10-12 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2006091798A2 (en) * 2005-02-22 2006-08-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus
EA026660B1 (ru) 2010-08-20 2017-05-31 Репликор Инк. Введение олигонуклеотидов в виде хелатных комплексов
ES2663009T3 (es) * 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
RS62030B1 (sr) 2012-05-18 2021-07-30 Replicor Inc Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201408309A (zh) * 2012-08-30 2014-03-01 Replicor Inc 用於治療ｂ型肝炎及ｄ型肝炎感染之方法

Also Published As

Publication number Publication date
MD4760B1 (ro) 2021-07-31
MD4760C8 (ro) 2022-02-28
WO2016004525A1 (en) 2016-01-14
JP2020143065A (ja) 2020-09-10
TW201613617A (en) 2016-04-16
BR112017000320A2 (pt) 2017-11-07
IL249660B (en) 2022-02-01
FI3166615T3 (fi) 2023-11-06
PL3166615T3 (pl) 2024-02-19
JP6922030B2 (ja) 2021-08-18
AU2015286199B2 (en) 2020-05-14
CN106659730A (zh) 2017-05-10
EP3166615A4 (en) 2018-01-17
IL249660A0 (en) 2017-02-28
KR20170029577A (ko) 2017-03-15
BR112017000320B1 (pt) 2023-02-07
CN113750112A (zh) 2021-12-07
EP3166615B1 (en) 2023-08-09
DK3166615T3 (da) 2023-11-13
HRP20231400T1 (hr) 2024-02-16
EA036745B1 (ru) 2020-12-16
ECSP16097355A (es) 2017-03-31
CL2017000008A1 (es) 2017-06-09
AU2015286199A1 (en) 2017-02-23
KR20230070330A (ko) 2023-05-22
LT3166615T (lt) 2024-01-25
PT3166615T (pt) 2023-11-13
US20160008393A1 (en) 2016-01-14
MY178087A (en) 2020-10-02
HK1231402A1 (zh) 2017-12-22
RS64833B1 (sr) 2023-12-29
SG11201700073PA (en) 2017-02-27
PH12017500010A1 (en) 2017-05-15
US9603865B2 (en) 2017-03-28
EP3166615A1 (en) 2017-05-17
NZ727583A (en) 2024-08-30
MD20170014A2 (ro) 2017-07-31
MX2017000053A (es) 2017-05-01
HUE064449T2 (hu) 2024-03-28
EA201790160A1 (ru) 2017-06-30
DOP2017000002A (es) 2017-03-15
CA2954182A1 (en) 2016-01-14
SI3166615T1 (sl) 2023-12-29
CA2954182C (en) 2023-08-15
ES2963814T3 (es) 2024-04-02
JP2017521433A (ja) 2017-08-03
CU20170001A7 (es) 2017-04-05

Similar Documents

Publication Publication Date Title
TWI766831B (zh) 具螯合錯合物及核苷/核苷酸類似物hbv聚合酶抑制劑之組合物及其用於治療hbv感染或hbv/hdv共感染之用途
JP6270846B2 (ja) Ｂ型肝炎感染及びｄ型肝炎感染の治療方法
US20180179542A1 (en) OLIGONUCLEOTIDE TARGETING STRATEGY FOR cccDNA
TW202221122A (zh) Ｂ型肝炎患者之寡核苷酸治療
WO2022022158A1 (zh) 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
EA039949B1 (ru) Способы лечения инфекций вирусом гепатита в и гепатита d